

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

6702540-2
PCT + SR
IPER +
Annexes

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 213/46, 213/64, 213/71, 213/75, 213/76, 295/192, 295/205, 239/34, 257/06, 317/62, 317/66, 405/12, C07C 311/21, 311/29, A61K 31/44	A1	(11) International Publication Number: WO 96/19455 (43) International Publication Date: 27 June 1996 (27.06.96)
(21) International Application Number: PCT/EP95/04762 (22) International Filing Date: 4 December 1995 (04.12.95) (30) Priority Data: 3838/94-8 20 December 1994 (20.12.94) CH 3079/95 31 October 1995 (31.10.95) CH (71) Applicant (for all designated States except US): F. HOFFMANN-LA ROCHE AG [CH/CH]; Grenzach- erstrasse 124, CH-4002 Basle (CH). (72) Inventors; and (75) Inventors/Applicants (for US only): BREU, Volker [DE/DE]; Belchenstrasse 7, D-79418 Schliengen (DE). BURRI, Kas- par [CH/CH]; Höhenweg 47, CH-4102 Binningen (CH). CASSAL, Jean-Marie [FR/FR]; 4, rue du Markstein, F- 68100 Mulhouse (FR). CLOZEL, Martine [FR/FR]; 11, rue Oberlin, F-68300 Saint-Louis (FR). HIRTH, Georges [FR/FR]; 7, rue de l'Ancre, F-68330 Huningue (FR). LÖFFLER, Bernd-Michael [DE/DE]; Seilhof 21, D-79206 Oberrimsingen (DE). MÜLLER, Marcel [CH/CH]; Quellen- weg 10, CH-4402 Frenkendorf (CH). NEIDHART, Werner [DE/FR]; 5, rue du Jura, F-68870 Bartenheim (FR). RA-		MUZ, Henri [CH/CH]; Rheinparkstrasse 3, CH-4127 Birs- felden (CH). (74) Agents: GROSSNER, Lutz et al.; P.O. Box 3255, CH-4002 Basle (CH). (81) Designated States: AL, AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, LS, MW, SD, SZ, UG). Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.
(54) Title: ARYL- AND HETARYL-SULFONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ENDOTHELIN ANTAGONISTS (57) Abstract Compounds of formula (I) wherein R¹ signifies phenyl, sub- stituted phenyl or heterocyclyl; R² signifies phenyl or substituted phenyl; R³ signifies hydrogen, lower-alkyl, cyano, carboxy, ester- ified carboxy, phenyl, substituted phenyl, heterocyclyl or a residue -CONR⁵R⁶ or -NR⁵COR⁷; R⁴ signifies hydrogen or lower-alkyl; R⁵ signifies hydrogen or a residue R⁷, and R⁶ signifies -(CH₂)_mR⁷; or R⁵ and R⁶ together with the N atom associated with them signify a heterocyclic residue; R⁷ signifies phenyl, substituted phenyl, cy- cloalkyl, heterocyclyl, lower-alkyl, cyano-lower-alkyl, hydroxy- lower-alkyl, di-lower-alkylamino-lower-alkyl, carboxy-lower-alkyl, lower-alkoxycarbonyl-lower-alkyl, lower-alkoxycarbonylamino-lower- alkyl or phenyl-lower-alkoxycarbonyl; R^a signifies hydrogen, lower-alkyl or hydroxy; R^b signifies hydrogen or lower-alkyl; Z signifies hydroxy, amino or a residue -OR⁸, -OC(O)NHR⁸, -OC(O)OR⁸, -NHC(O)NHR⁸ or -NHC(O)OR⁸; R⁸ signifies heterocyclyl, phenyl, sub- stituted phenyl or lower-alkyl; A and Y each independently signify oxygen or sulphur; X signifies nitrogen or CH; m signifies 0, 1 or 2; and n signifies 0, 1 or 2; and pharmaceutically usable salts thereof are inhibitors of endothelin receptors. They can therefore be used for the treatment of disorders which are associated with endothelin activities, especially circulatory disorders such as hypertension, ischaemia, vasospasms and angina pectoris. (I)		